Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Pingyu Chen"'
Publikováno v:
BMC Health Services Research, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Background Esophageal carcinoma is a type of cancer that occurs in the esophagus. For patients with locally advanced or metastatic esophageal squamous cell carcinoma who have either experienced disease progression following first-line standa
Externí odkaz:
https://doaj.org/article/499d5a4733ec48faba7c4305176eb243
Publikováno v:
Health Economics Review, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Background Clinical trials have demonstrated the efficacy of edaravone dexborneol in the treatment of acute ischemic stroke. This study aims to determine the cost-effectiveness of edaravone dexborneol compared with human urinary kallidinogen
Externí odkaz:
https://doaj.org/article/82810219928a43ceab5db36337650a34
Autor:
Pingyu Chen, Xintian Wang, Shengwen Zhu, Hongchao Li, Mingjun Rui, Yingcheng Wang, Haikui Sun, Aixia Ma
Publikováno v:
Frontiers in Public Health, Vol 10 (2022)
Background and objectiveSintilimab has superior efficacy and safety in patients with advanced or metastatic squamous non-small cell lung cancer (NSCLC), but its cost-effectiveness in China is unclear. This study is to evaluate the cost-effectiveness
Externí odkaz:
https://doaj.org/article/872b02322ff74c83bb6f16d3b812a00e
Publikováno v:
Health and Quality of Life Outcomes, Vol 19, Iss 1, Pp 1-13 (2021)
Abstract Objective This study aimed to conduct a systematic review and meta-analysis to compare differences in health utilities (HUs) assessed by self and proxy respondents in children, as well as to evaluate the effects of health conditions, valuati
Externí odkaz:
https://doaj.org/article/d0d961dd106645ccace0adeeb5f2647d
Autor:
Mengran Zhang, Pingyu Chen, Yan Zhang, Xi Su, Jiyan Chen, Biao Xu, Jianhong Tao, Zhen Wang, Hongchao Li, Aixia Ma
Publikováno v:
Frontiers in Public Health, Vol 9 (2021)
Background: Dyslipidemia is an important risk factor for myocardial infarction (MI). This study aimed to examine the health-related quality of life (HRQoL) and its predictors of patients with MI combined with dyslipidemia in China.Methods: Informatio
Externí odkaz:
https://doaj.org/article/074382b4da81473d9ea1b37e3c3fbb8d
Publikováno v:
Frontiers in Medicine, Vol 8 (2021)
Introduction: This study evaluated the cost-effectiveness of abemaciclib plus fulvestrant (ABE + FUL) vs. palbociclib plus fulvestrant (PAL + FUL), ribociclib plus fulvestrant (RIB + FUL) and fulvestrant monotherapy (FUL) as second-line treatment for
Externí odkaz:
https://doaj.org/article/2e66660a784f41e28c593e8322180495
Publikováno v:
Frontiers in Public Health, Vol 9 (2021)
Background: Health-related quality of life (HRQoL) is one of the major focuses of primary care. However, HRQoL instruments used in China are mainly developed from Western countries. Such instruments may not cover all important health concepts valued
Externí odkaz:
https://doaj.org/article/94c2b60512f047bc878492df57134177
Autor:
Pingyu Chen, Mengran Zhang, Yan Zhang, Xi Su, Jiyan Chen, Biao Xu, Jianhong Tao, Zhen Wang, Aixia Ma, Hongchao Li
Publikováno v:
Frontiers in Public Health, Vol 9 (2021)
Background: Dyslipidemia is a common comorbidity and an important risk factor for myocardial infarction (MI). This study aimed to examine the economic burden of MI combined with dyslipidemia in China.Methods: Patients who were hospitalized due to MI
Externí odkaz:
https://doaj.org/article/464aca7bf5df427db16c97132dc9d187
Publikováno v:
Indian Journal of Microbiology. 63:106-119
There is a symbiotic relationship between gut microbiota and human beings. Imbalance of the gut microbiota will cause pathological damages to humans. Although many risk factors are associated with missed abortion (MA), the pathological mechanism of i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c2795709a06410459d36c7601f15635
https://doi.org/10.1007/s12088-023-01063-y
https://doi.org/10.1007/s12088-023-01063-y
Background Tislelizumab is a selective PD-1 inhibitor with efficacy proven in locally advanced or metastatic esophageal squamous cell carcinoma. The study aims to evaluate the cost-effectiveness of tislelizumab versus camrelizumab as the second-line
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30a5ae9f901e495f7cee9350f89efffd
https://doi.org/10.21203/rs.3.rs-2788874/v1
https://doi.org/10.21203/rs.3.rs-2788874/v1
